



Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Health Advance Inc.

9131 Keele Street, Suite A4
Vaughan, Ontario, Canada L4K 0G7
(705) 733-7098

www.HealthAdvanceGroup.com

President@HealthAdvanceGroup.com

SIC Code 5990 - Retail-Retail Stores – Other Specialty Retail

Quarterly Report

For the Three Months Ending September 30, 2024
(the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

339,541,191 as of the end of this reporting period, September 30, 2024
185,947,500 as of the end of the most recent fiscal year, March 31, 2024

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

¹ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

HEALTH ADVANCE INC.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

WYOMING, APRIL 14, 2010, ACTIVE

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

The address(es) of the issuer's principal executive office:

9131 KEELE STREET, SUITE A4
VAUGHAN, ONTARIO L4K 0G7
CANADA

The address(es) of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:

2) Security Information

Transfer Agent

Equity Trust Company, LLC
48 Wall Street, Floor 23
New York, New York
10005

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	HADV		
Exact title and class of securities outstanding:	COMMON SHARES		
CUSIP:	42225L203		
Par or stated value:	.001		
Total shares authorized:	500,000,000	as of date:	Sep 30, 2024
Total shares outstanding:	339,541,191	as of date:	Sep 30, 2024
Total number of shareholders of record:	72	as of date:	Sep 30, 2024

All additional class(es) of publicly quoted or traded securities (if any): Not Applicable

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

One vote per share. No special dividend, voting and preemption rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

None issued during the reporting period. A correction to a 2017 Board of Directors resolution filed at that time with the State of Wyoming, in which a Series A Preferred Share Class was authorized to be created (but none were issued), will be filed to include a Certificate of Designation outlining the characteristics and quantity of the Preferred Shares. The correction will consist of the insertion of a missing "Schedule A".

3. Describe any other material rights of common or preferred stockholders.

There are no undisclosed material enforceable rights, beyond the circumstances of the issuer as described in the issuer's filings. The reader is encouraged to read all notes to all tables in this report and notes to the financial statements in this report, and to read and understand the disclosure of the Annual Reports for the years ending March 31, 2020 - 2024 in order to understand the issuer's history, and the evolution of its management (and policies).

4. Describe any material modifications to the rights of holders of the company's securities that have occurred over the reporting period covered by this report.

Not applicable.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: March 31, 2022									
<u>Opening Balance</u>									
Date April 1/2022									
Common: 160,947,500									
Preferred: N/A									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
Apr 25/22	New	12,500,000	Common	0.01	No	JP Carey Enterprises, LP/ Joe Canouse	Working Capital	Unrestricted	Approved Regulation A+
May 02/22	New	12,500,000	Common	0.01	No	World Market Ventures/ Chad Curtis	Working Capital	Unrestricted	Approved Regulation A+
Jun 27/24	New	18,421,052	Common	.0011	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Jul 17/24	New	22,174,535	Common	.0007	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Aug 09/24	New	24,393,939	Common	.00066	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Aug 20/24	New	26,833,333	Common	.0006	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Sep 04/24	New	29,479,166	Common	.000048	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144
Sep 23/24	New	32,291,666	Common	.000048	Yes	JP Carey Limited Partners LP	Debt Conversion	Unrestricted	Rule 144

Shares Outstanding on Date of This Report:

Ending Balance:

Date Sep 30, 2024

Common: 339,541,191

Preferred: N/A

GENERAL ADVISORY COMMENT

The shares issued in 2022 were pursuant to an approved Regulation A+ offering.

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities :

No: Yes: X (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
Mar 10/17	15,337.00	10,000.00	5,337.00	Mar 03/18	Cash or Convertible at 40%	GHS Investments/ Mark Grober	Working Capital Note 1
Mar 31/19	61,935.90 (Fluctuates)	2,500.00	TBD	Demand Loan	Repayable in Cash or Equity, TBD	Fit For A King Inc, Gerald Pettle	Working Capital Note 2
May 25/21	20,697.33	20,697.33	TBD	May 25/22	Convertible at \$0.025	Sydney Bernstein	Working Capital Note 3
May 27/21	20,697.33	20,697.33	TBD	May 27/22	Convertible at \$0.025	Arthur Stemerman	Working Capital Note 4
Jun 02/21	20,697.33	20,697.33	TBD	Jun 02/22	Convertible at \$0.025	Originally Luigi Buttino; Purchased by Gerald Pettle	Working Capital Note 5
July 07/21	20,697.33	20,697.33	TBD	Jul 07/22	Convertible at \$0.025	Ne'eman Foundation Canada Charm Katz	Working Capital Note 6
Oct 27/21	72,000.00	72,000.00	TBD	Oct 27/22	40%	J.P.Carey Limited Partnership/ Joe Canouse	Working Capital Note 7
Jan 27/22	57,000.00	57,000.00	TBD	Jan 27/23	40%	J.P.Carey Limited Partnership/ Joe Canouse	Working Capital Note 8

Note 1

The holder has agreed to convert for equity when suitable and possible.

Note 2

Fit For A King, Inc, the owner of record of approximately 30 million common shares, and Fit For A King's beneficial owner, Gerald Pettle, undertook to provide the issuer with working capital in 2020, and as possible thereafter. This was to be for the purpose of attaining OTC Markets current information designation, as well as for the issuer to attain good standing with any other applicable regulatory bodies and suppliers. Compensation to Mr. Pettle is to be eventual repayment in cash with bonus and/or shares, to be determined. Additional possible financial compensation to Mr. Pettle was to be linked to, and/or governed by, the success of business ventures that Mr. Pettle would bring to the issuer in the past, present or future. Such compensation

can also either take the form of cash and/or shares. Compensation to Mr. Pettle for earlier assistance will be determined by the issuer's circumstances at the time(s) that compensation to Mr. Pettle is made. Determinations at such time(s) will also take into account compensation required for 3rd parties who are performing supportive roles in retaining OTC Markets good standing, paying other regulatory compliance costs, retiring creditor obligations, and funding or operating business projects. This accommodation of 3rd parties will include compensation to issuer management to market norm standards currently and retroactively, third-party consultants, and any other compensatory arrangements with parties, including staff, who contribute to attainment of the issuer's goals, or payment by them on behalf of the issuer for costs or processes needed to operate the issuer's business.

Note 3

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

Note 4

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

Note 5

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion and that the note has been purchased by Gerald Pettle, according to details to be confirmed.

Note 6

At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

Note 7

At the time of the filing of this report, this note is in default. Remediating the default is being discussed with the creditor and involves special interest and/or penalties to be determined as conversions are effected. A restatement of the principal amount due may be required to reflect the specifics of such forbearance.

Note 8

At the time of the filing of this report, this note is in default. Remediating the default is being discussed with the creditor and involves special interest and/or penalties to be determined as conversion are effected. A restatement of the principal amount due may be required to reflect the specifics of such forbearance.

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

CBD BEVERAGES LEADING TO THE CANNABIS SECTOR MORE BROADLY and ADDITIONAL OPPORTUNITIES

In earlier reporting periods, Health Advance Inc had taken steps to launch proprietary CBD infused dealcoholized wine beverage products and to investigate the viability of launching proprietary nutraceutical products.

Health Advance's test CBD beverage production took place via the operating entity Courtship Wines, a New York private company, of which Health Advance is 50% owner. Negotiations for the sale of this test production had been underway with a U.S. regional grocery chain operating approximately 400 stores. The prospective customer stipulated conditions which the issuer had been evaluating. These conditions included repackaging the goods, guaranteed sale, etc. It was determined by the project management team that test marketing through a brand-owned website would be more fruitful because it could be carried out sooner, without changes to the product. Test sales to consumers were carried out.

By March 31, 2024, the date of the issuer's last annual report, management of the issuer derived the following conclusion from the aforementioned test marketing - Health Advance should seek an alternative approach to cannabis related business opportunities, rather than CBD infusion of wine. Focus will be on a merger or alliance with an entity that has existing sales and the prospect of immediate profitability.

Accordingly, as of the Quarterly reporting period of the three months ending June 30, 2024, Health Advance Inc has entered into joint venture negotiations with emergent cannabis processing operation, Coulson Cannabis. The operation is licensed by the Government of Canada to supply cannabis and related products for medical and recreational use. At the time of

negotiations, Coulson Cannabis has existing sales of approximately \$1 Million per year. These sales are trending upward. Customers include government and large respected cannabis marketers within the industry. Health Advance is negotiating to become a partial owner of Coulson Cannabis in return for investment, and then to deploy a growth strategy. Health Advance and Coulson management estimate that Coulson sales of existing products through existing channels can increase by 10 - 50 times in volume, rapidly and profitably, following payment of listing fees within the Canadian cannabis distribution environment. This could expand sales from \$1 Million per year to \$10 - \$50 Million per year. The listing fees for this purpose would be approximately \$500,000. Alternatively, such listing fees could be self-financed by Coulson Cannabis if that company were relieved of its debt servicing costs. Coulson Cannabis has cannabis industry contacts and operating plans to expand to the USA market as well. Coulson Cannabis has experience in CBD derivatives extraction, production of gummies and other market variants that create expansion opportunities in scope, not only scale. USA cannabis market regulations and dynamics are increasingly favorable to well-positioned participants, such as Coulson Cannabis.

HADV management has provided public notice on its Twitter/X account of a Letter of Intent for a joint venture of this nature. Twitter/X is the issuer's only social media account and provides a level playing field for all investors, whether they are existing shareholders or not, by providing timely access to management's current thinking, and to have questions answered. Additional negotiations are underway with parties in the field of health and well-being of indigenous communities, and their economic vibrancy. More information about these possibilities will be announced as soon as possible.

Some of the Coulson Cannabis team members outside the primary production site:



B. List any subsidiaries, parent company, or affiliated companies.

Affiliated: Courtship Wines, Inc. New York State. 50% The entity is treated as separate for accounting purposes, as a JV, rather than being combined and consolidated for reporting purposes, due to split voting control. It is anticipated that this entity will be wound down. This would result in the write-off of an unrecovered debt.

C. Describe the issuers' principal products or services.

- CBD infused dealcoholized wine, subject to commercial customer vetting. Testing, likely new variants required.
- Immune boosting nutraceutical in viability analysis. Market research stage.

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used, or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties, or facilities of the issuer, give the location of the principal plants and other property of the issuer, and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties, or facilities, clearly describe them as above and the terms of their leases.

Health Advance former management was in the past not local to the Company's official business address. Current management has rectified this situation, as shown below in the photograph of Health Advance Inc physical business address.



Health Advance occupies a modern shared-use office premises within reasonable proximity of management, consultants, and service providers.



The facility accommodates all foreseeable meeting and collaboration requirements at modest rent within industry norms.

6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.** Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer. The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling, or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Larry McLachlin	President	Blue Mountains, Ontario, Canada	80,000	N/A	.0003%	Purchased at Prevailing Market
Micro MedTech/ Windell Abraham See Note A	Owner of more than 5%	Pohnpei, Micronesia	40,000,000	Common	12%	Windell Abraham, Pohnpei, Micronesia
Fit For A King/ Gerald Pettle	Owner of more than 5%	Richmond Hill, Ontario, Canada	30,005,500	Common	9%	Gerald Pettle, Richmond Hill, Ontario

Note A: These shares, which had formed part of a voting arrangement that conveys continuing proxy to operating management, were subject to certain performance expectations during a vesting period at the time of issuance. These shares have been, and are still, subject to review and cancellation by the issuer at any time for contract reasons without further notice, as attested to by the publication of this advisory, which is made as a courtesy to any affected parties continuously. This advisory is made without waiving the cancellation rights of the issuer.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
NO
2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial or investment related, insurance or banking activities;
NO
3. Been the subject of a finding, disciplinary order, or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulator body or court, which finding, or judgment, has not been reversed, suspended, or vacated;
NO
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities;
NO
5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities;
NO
6. Been the subject of a U.S. Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S. mail;
NO

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NOT APPLICABLE

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel

Name: VIC DEVLAEINCK
Firm: ATTORNEY - CPA
Address 1: 100013 N.E.HAZEL DELL AVENUE, SUITE 317
Address 2: VANCOUVER, WASHINGTON, 98685
Phone: (503) 806-3533
Email: VIC@VICDEVLAEINCK.COM

Accountant

Name: INTERNAL

Investor Relations

Name: INTERNAL

All other means of Investor Communication:

Twitter: www.Twitter.com/HADVPresident

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Firm: Winning Brands Corporation (Delaware)
Nature of Services: Consulting
Address 1: C/O National Registered Agents
Address 2: 160 Greentree Drive, Suite 101, Dover, DE 19904
Phone: (705) 737-4062
Email: CustomerService@WinningBrands.ca

9) Financial Statements

A This Disclosure Statement was prepared by

Name	Larry McLachlin
Title	President
Relationship	Officer of Health Advance

B The following financial statements were prepared in accordance with:

IFRS

U.S. GAAP

C The following financial statements were prepared by (name of individual)²:

Name: Daniela Relja
Title: ProtectCor Services
Relationship: Bookkeeping and Administrative Service Provider

Describe the qualifications of the person or persons who prepared the financial statements: 5 Years Direct Experience

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

Important Notes:

- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- All financial statements for a fiscal period must be published together with the disclosure statement in one Annual or Quarterly Report.

² The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

10) Issuer Certification

Principal Executive and Financial Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Larry McLachlin, certify that:

1. I have reviewed this Disclosure Statement for Health Advance Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 14, 2024

/s/ LARRY MCLACHLIN

CHAIRMAN & CEO

Financial Statements of Health Advance, Inc

For the Three Months Ending September 30, 2024

(Unaudited)

*These financial statements are to be read in conjunction with the accompanying notes,
which form an integral part of their presentation.*

Health Advance Inc.

Balance Sheet

As of September 30, 2024

(Unaudited)

	TOTAL	
	AS OF SEP. 30, 2024	AS OF SEP. 30, 2023 (PY)
Assets		
Current Assets		
Cash and Cash Equivalent	\$ -316.56	\$1,104.64
Accounts Receivable (A/R)	\$36,225.99	\$36,225.99
Loan to Courtship Wines (CDN Funds)	91,417.31	91,417.31
Loan to Courtship Wines (USD Funds)	191,700.00	191,700.00
Total Current Assets	\$319,026.74	\$320,447.94
Non-current Assets		
Property, plant and equipment	\$1,648.62	\$1,648.62
Intellectual Property	180,000.00	180,000.00
Total Non Current Assets	\$181,648.62	\$181,648.62
Total Assets	\$500,675.36	\$502,096.56
Liabilities and Equity		
Liabilities		
Current Liabilities		
Accounts Payable (A/P)	\$280,724.78	\$247,705.46
Accrued Liabilities	2,500.00	2,500.00
Loan (Short Term) from HADV President	8,664.81	7,764.81
Loan (Short Term) from Investor	17,440.00	
Loan (Short Term) from new JV Partner	8,649.99	9,459.20
Total Current Liabilities	\$317,979.58	\$267,429.47
Non-current Liabilities	\$254,071.33	\$254,071.33
Total Liabilities	\$572,050.91	\$521,500.80
Equity		
Accumulated Deficit	-437,495.00	-437,495.00
Additional Paid-In Capital	186,080.00	186,080.00
Common Stock	553,062.00	553,062.00
Common Stock to be Issued	67,500.00	67,500.00
Retained Earnings	-411,199.83	-362,108.47
Profit for the year	-29,322.72	-26,442.77
Total Equity	\$ -71,375.55	\$ -19,404.24
Total Liabilities and Equity	\$500,675.36	\$502,096.56

Health Advance Inc.

Profit and Loss

July - September, 2024

(Unaudited)

	TOTAL	
	JUL - SEP., 2024	JUL - SEP., 2023 (PY)
EXPENSES		
Bank Charges	113.17	69.73
Business Travel Expenses	417.67	
Compliance and Transfer Agent	8,115.00	7,013.60
Executive Compensation	3,284.05	3,368.62
Interest expense		371.91
IT Expenses	62.33	115.17
Occupancy	214.65	159.48
Office Administration and Bookkeeping	5,207.38	4,694.49
Sales Tax Paid	43.22	48.61
Total Expenses	\$17,457.47	\$15,841.61
OTHER EXPENSES		
Exchange Gain or Loss	259.31	7.07
Total Other Expenses	\$259.31	\$7.07
PROFIT	\$ -17,716.78	\$ -15,848.68

Health Advance Inc.

Statement of Cash Flows

July - September, 2024

(Unaudited)

	TOTAL
OPERATING ACTIVITIES	
Net Income	-17,716.78
Adjustments to reconcile Net Income to Net Cash provided by operations:	
Accounts Payable (A/P) - CAD Suppliers (USD)	7,082.52
Accounts Payable (A/P) - US Suppliers (USD)	675.00
Loan (Short Term) from Investor	10,940.00
Loan (Short Term) from new JV Partner	-1,142.05
Total Adjustments to reconcile Net Income to Net Cash provided by operations:	17,555.47
Net cash provided by operating activities	\$ -161.31
NET CASH INCREASE FOR PERIOD	\$ -161.31
Cash at beginning of period	-155.25
CASH AT END OF PERIOD	\$ -316.56

Health Advance Inc.

Statement of changes in equity

As of September 30, 2024

(Unaudited)

	TOTAL	
	AS OF SEP. 30, 2024	AS OF SEP. 30, 2023 (PY)
Accumulated Deficit	-437,495.00	-437,495.00
Additional Paid-In Capital	186,080.00	186,080.00
Common Stock	553,062.00	553,062.00
Common Stock to be Issued	67,500.00	67,500.00
Retained Earnings	-411,199.83	-362,108.47
Total Equity	\$ -42,052.83	\$7,038.53

NOTES TO THE FINANCIAL STATEMENTS OF HEALTH ADVANCE INC

For the Three Months Ending September 30, 2024

1. NATURE OF OPERATIONS AND ORGANIZATION

Health Advance Inc. (the “Company” or “Health Advance”) was incorporated on April 14, 2010 in the State of Wyoming. The Company was originally a development stage online retailer of home medical products. Since that time, the Company has pursued broader business opportunities in the field of human wellness. The Company is in good standing with the State of Wyoming.

2. BASIS OF PRESENTATION

The condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the USA for the Alternative Reporting Guidelines of OTC Markets. All adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. Restatement of capital stock attributed value, and additional paid in contributions, will be made when required in future financial statements, without amendment of prior reporting, in order to reflect the interest impact of negotiated settlement of loans in forbearance, or changes to the convertibility of promissory notes and other obligations, when applicable negotiations are completed.

3. GOING CONCERN

These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses, historically, and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management seeks sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

4. PROFIT / LOSS PER SHARE

The Company has not yet adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive.

5. ACCOUNTING PRONOUNCEMENTS

Periodically Issued Accounting Standards

The Company has not yet adopted all accounting pronouncements issued by the Financial Accounting Standards Board ("FASB") that would apply to SEC reporting issuers, which Health Advance is not. For illustration only, the guidance on how companies account for certain aspects of share-based payments to employees, This pronouncement, for illustration, became effective for fiscal years beginning after December 15, 2016. This guidance called for income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers' accounting for an employee's use of shares to satisfy the employer's statutory income tax withholding obligation. In the opinion of management adoption of this pronouncement in particular, and similar pronouncements in general, would not have a material impact on Company's financial position and/or results of operations until such time that the scale of the Company's operation expands considerably. The cost and complexity of applying such measures are not feasible, or material, for the Company at the present time. Readers are therefore cautioned that these unaudited internal financial statements may not be suitable for their purposes, notwithstanding the attempt within these statements to present fairly the material conditions of the Company.

6. RELATED PARTY TRANSACTIONS AND BALANCES

The transactions with any related parties are kept within standards that would apply to arm's length transactions unless otherwise specified in the Company's disclosures. Principal amongst non-arm's length transactions are the compensation agreements between the sole director representing shareholders and the president, who are the same person. To mitigate this, compensation is kept within reasonable norms for public company service of this nature, with similar responsibilities and similar risk associated with the exercise of fiduciary responsibilities, including public and regulatory accountability.

7. CONTINUITY

The financial statements of Health Advance were audited up to and including the 2016 fiscal year. Former management undertook to vend in business projects that would have required international auditing that exceeded the company's financial resources relative to the potential value of the vend-in. Former management did not therefore carry on with auditing. The current information disclosure filed with OTC Markets under the Alternative Reporting Guidelines resets to the present from the last audited trial balance, rather than from the unaudited EDGAR Q filings, and does not merge largely non-cash subsequent activity in the interests of present clarity and reality. Only known assets are recorded. Liabilities which are statute-barred or forgiven are reflected as recoveries. This serves the cause of accuracy of the current information by avoiding unsubstantiated presumptions, and restoring simple, materially reliable and up-to-date presentation of the present conditions. Management believes that no taxes are payable due to the absence of profit to-date and substantial tax loss carry-forwards. The Company may amend any aspect of the financial statements and other disclosure if new information calls for restatement of any fact.